



(51) International Patent Classification:

A61K 47/60 (2017.01) A61K 49/12 (2006.01)
 A61K 47/54 (2017.01) A61K 51/06 (2006.01)
 A61K 47/56 (2017.01) C07D 487/00 (2006.01)
 C08G 73/02 (2006.01) C07D 305/14 (2006.01)
 C08L 101/00 (2006.01) A61K 47/68 (2017.01)
 A61K 47/62 (2017.01) A61P 35/00 (2006.01)
 A61K 47/64 (2017.01)

(21) International Application Number:

PCT/AU2021/050554

(22) International Filing Date:

03 June 2021 (03.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2020901833 03 June 2020 (03.06.2020) AU

(71) Applicant: **STARPHARMA PTY LTD** [AU/AU]; 4-6
 Southampton Crescent, Abbotsford, Victoria 3067 (AU).

(72) Inventors: **SHENGULE, Sudhir Ramnathrao**; C/O-
 Starpharma Pty Ltd, 4-6 Southampton Crescent, Abbots-

ford, Victoria 3067 (AU). **OWEN, David**; C/O- Starpharma Pty Ltd, 4-6 Southampton Crescent, Abbotsford, Victoria 3067 (AU). **HUFTON, Richard**; C/O- Starpharma Pty Ltd, 4-6 Southampton Crescent, Abbotsford, Victoria 3067 (AU). **THURECHT, Kris**; C/O- Starpharma Pty Ltd, 4-6 Southampton Crescent, Abbotsford, Victoria 3067 (AU).

(74) Agent: **FB RICE PTY LTD**; Level 33, 477 Collins St, Melbourne, Victoria 3000 (AU).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: THERAPEUTIC CONJUGATES




Fig. 7

(57) Abstract: Provided herein is dendrimer-targeting agent conjugate comprising: (a) a dendrimer comprising i) a core unit (C); and ii) building units (BU), wherein the dendrimer has from two to six generations of building units; and wherein the core unit is covalently attached to at least two building units; and the dendrimer further comprising: b) a targeting agent which is covalently linked to the dendrimer by a spacer group; c) one or more first terminal groups attached to an outermost building unit of the dendrimer, wherein the first terminal group comprises a complexation group for complexing a radionuclide; and d) one or more second terminal groups attached to an outermost building unit of the dendrimer, wherein the second terminal group comprises a pharmacokinetic-modifying moiety, or a salt thereof. Also provided are compositions comprising the dendrimer-targeting agent conjugates, and methods of using the dendrimer-targeting agent conjugates and compositions comprising them in therapeutic and imaging applications.

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*